

TAYSIDE PRESCRIBER

Tayside DTC Supplement No 79

May 2008

Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

SMC Advice issued in May 2008

Medicine	Indication	Local recommendation category	Comments and useful links
Aliskiren (Razilex [®]) - <i>Non submission</i>	Essential Hypertension	Not recommended	SMC advice
Escitalopram (Cipralex [®]) - <i>Non submission</i>	Social Anxiety Disorder	Not recommended	SMC advice
Imiquimod (Aldara [®]) - <i>Re-submission</i>	Actinic keratoses on the face and scalp in immunocompetent adults	Pending approval of local protocol	SMC advice SPC link
Lenalidomide (Revlimid [®])	Multiple myeloma in combination with dexamethasone in patients who have received at least one prior therapy	Not recommended	SMC advice
Raltegravir (Isentress [®])	HIV-1 infection	HOSPITAL ONLY (HIV clinic)	SMC advice SPC link

[Click here](#) for May 08 SMC briefing note

Updates from previous SMC advice in March/April 2008

Medicine	Indication	Local recommendation category	Comments and useful links
Daptomycin 350mg & 500mg vials (Cubicin [®])	<i>Staphylococcus aureus</i> bacteraemia associated with right sided infective endocarditis or skin and soft tissue infections	HOSPITAL ONLY Restricted to use in patients with known or suspected methicillin resistant <i>S.aureus</i> infection. All use must have prior authorisation by ID or microbiology.	SMC advice SPC link Alert anti-infective
Efavirenz, emtricitabine, tenofovir (Atripla [®]) <i>Abbreviated submission</i>	HIV-1 infection	HOSPITAL ONLY (HIV clinic)	SMC advice SPC link
Nelarabine (Atriance [®])	T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) unresponsive/relapsed after at least two chemotherapy regimens	<i>Adults</i> HOSPITAL ONLY (haematology clinic) <i>Children</i> Restricted to tertiary paediatric oncology centres	SMC advice SPC link
Telbivudine 600mg film-coated tablets (Sebivo [®])	Treatment of chronic hepatitis B	Non formulary medicine - not recommended in Tayside	SMC advice New hepatitis B treatment guideline being developed

TAPG Update

	TAPG section	Drug(s)/topic	Changes
3	Respiratory System	Beclometasone CFC inhaler	Beclometasone changed from CFC to CFC-free Qvar [®] and Clenil Modulite [®] ▼ inhalers. Information on licensed use added (Clenil Modulite [®] ▼ - no age restrictions; Qvar [®] - adults and children over 12 years). Link to Tayside Prescriber on switching from CFC beclometasone added.
3	Respiratory System Guidelines	Guidance on Inhaler Devices 12 years+	Becotide [®] removed from spacer device table and replaced with Clenil Modulite [®] ▼. Statement on HandiHaler [®] only available for tiotropium removed. Beclometasone CFC MDI removed from conversion table and replaced with Clenil Modulite [®] ▼. Further dose information added to conversion table.
6	Endocrine	Dydrogesterone	Dydrogesterone 10mg tablets removed as discontinued. Expansion to risk/benefit section for tibolone in women over 60 years. Femoston [®] 2/20 removed as discontinued.
13.4	Topical Corticosteroids	Corticosteroids with antimicrobial agents	Addition of Betnovate-C [®] and expansion on use of Fucibet [®] .
13.6	Preparations for Acne	Oral antibiotics	Addition of lymecycline. Expansion of recommended duration for Dianette [®] .
13.9	Shampoos and Scalp Applications	Betadine [®]	Betadine [®] removed as discontinued.
13.10	Anti-infective skin preparations	Treatment of Lice and Scabies	Dimeticone (Hedrin [®]) added to reflect new NHS Tayside policy for control of head lice infection due to be published shortly.
13	Skin Guidance Notes	Management of Acne	Lymecycline added to replace minocycline.
		Management of Psoriasis	Calcipotriol scalp application added. Advice on sunbeds added.
		Management of Scabies	Updated to reflect new NHS Tayside policy for control of scabies infection due to be published shortly.
		Management of Warts	Addition of comment on aerosol cryotherapy devices.
		Use of Topical Corticosteroids	Addition of further good practice points.

Bisphosphonates in post- menopausal osteoporosis: An Update

The 3-monthly injection of intravenous ibandronic acid 3mg/3ml (Bonviva[®]) for restricted use in post-menopausal osteoporosis is no longer recommended in NHS Tayside. Once existing stocks have been used, it will no longer be stocked by the Hospital Pharmacy Department.

Zoledronic acid infusion 5mg/100ml (once a year) is now recommended for this indication.

Forthcoming SMC Advice

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access to the NHS Tayside Drug and Therapeutics Committee website (www.nhstaysideadtc.scot.nhs.uk).